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ABSTRACT
A reduction in trabecular bone mass is often associated with an increase in marrow fat in osteoporotic bones. The molecular
mechanisms underlying this inverse correlation are incompletely understood. Here, we report that mice lacking tuberous sclerosis 1
(Tsc1) in Osterix-expressing cells had a significant decrease in trabecular bone mass characterized by decreased osteoblastogenesis,
increased osteoclastogenesis, and increased bone marrow adiposity in vivo. In vitro study showed that Tsc1-deficient bone marrow
stromal cells (BMSCs) had decreased proliferation, decreased osteogenic differentiation, and increased adipogenic differentiation in
associationwith the downregulation ofWnt/b-catenin signaling. Mechanistically, TSC1 deficiency led to autophagy suppression and
consequent Notch1 protein increase, whichmediated the GSK3b-independentb-catenin degradation. Together, our results indicate
that Tsc1 controls the balance between osteoblast and adipocyte differentiation of BMSCs. © 2018 American Society for Bone and
Mineral Research.
KEY WORDS: OSTEOBLAST; ADIPOCYTE; TSC1; WNT, B-CATENIN; BONE MARROW; NOTCH1; AUTOPHAGY
Introduction
An increase in marrow adipose tissue often accompanies adecrease in bone mass in osteoporosis(1) and other
conditions that induce bone loss.(2–4) This inverse relationship
is also reported inmousemodels, which provide important tools
to determine underlying molecular mechanisms. Multipotent
bone marrow stromal cells (BMSCs) can differentiate into both
adipocytes and osteoblasts upon specific stimulation for cell
differentiation. The osteoblast-adipocyte lineage commitment
of BMSCs has direct relevance to the regulation of bone
development and the maintenance of bone homeostasis.
The insight into the molecular mechanisms governing the
balance between osteoblast and adipocyte differentiation in
bone marrow can facilitate developing new therapies to treat
osteoporosis and other bone loss conditions.
Wnt/b-catenin signaling regulates both osteoblastogenesis
and adipogenesis.(5,6) b-catenin conditional knockout in osteo-
blast progenitor cells decreases bone mass and increases bone
marrow adiposity.(7,8) b-catenin deficient BMSCs have decreased
osteogenic but enhanced adipogenic ability.(7) It has been
demonstrated that core-binding factor subunit beta controls the
balance between osteoblast and adipocyte lineage through
promotingWnt/b-catenin signaling.(9) Similarly, we showed that
focal adhesion kinase inhibits the adipogenic differentiation
potential and enhances the osteogenic differentiation potential
of BMSCs through enhancing b-catenin signaling.(10)
Mechanistic target of rapamycin complex 1 (mTORC1) plays
critical roles in cell growth, cellular metabolism, and autoph-
agy.(11,12) Tuberous sclerosis complex 1 (TSC1) and TSC2 are tumor
suppressor genes and TSC1/TSC2 complex is an upstream
inhibitor of mTORC1.(13) Germline mutations in either TSC1 or
TSC2 leads to the activation of mTORC1 signaling and causes a
human disease called tuberous sclerosis with a birth rate of 1 in
5800, characterized by the presence of benign congenital tumors
in multiple organs.(14,15) Osseous manifestations of tuberous
sclerosis are very diverse and complex, including calvaria
hyperostosis, periosteal new bone formation, osteoporotic lesion
in hand bones, and cyst-like radiolucent lesions.(16,17) Recently,
Tsc1 or Tsc2 mutation mouse models have been used to
determine the impact and mechanisms of upregulated mTORC1
signaling in bone homeostasis. Tsc2 deletion in mature
osteoblasts(18) and Tsc1 deletion in osteoblast progenitors(19)
both lead to increasedbonemass.Hypomineralization, decreased
bone mineral density, and/or greatly increased cortical porosity
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are reported in these twomodels. In contrast, we found that Tsc1
deletion in neural crest–derived cells results in an increase in
craniofacial bone mass in association with a hypermineralization
phenotype.(20,21) The phenotypic difference among these mouse
models highlighted the complexity of mTORC1 regulation on
bone homeostasis. To further determine the role of TSC1/
mTORC1 signaling in bone homeostasis, we generated a Tsc1
conditional knockout mouse model by deleting Tsc1 in Osterix-
expressing cells.We showed that Tsc1deletion led toadecrease in
trabecular bone mass in association with an increase in bone
marrow adiposity and a decrease inWnt/b-catenin signaling. Our
data indicate that Tsc1 is a novel regulator governing the
osteoblast-adipocyte differentiation in bone marrow.
Materials and Methods
Mice
The generation of floxed Tsc1 (Tsc1F/F), floxed Fip200 (Fip200F/F),
Osterix-Cre (Osx-Cre), and GFP-LC3 transgenic mice has been
reported.(22–25) All mice were in a C57BL/6 background after at
least eight-generation backcrossing. Tsc1F/F micewere bredwith
Osx-Cre/þ mice to generate male Tsc1F/þ;Osx-Cre/þ (CHet)
mice. Male CHet mice were then bred with female Tsc1F/þ mice
to generate Tsc1F/F;Osx-Cre/þ (conditional knockout [CKO]),
CHet, and Osx-Cre/þ (Osx-Cre) mice. In some experiments, CHet
mice were bred with Tsc1F/F mice to generate Tsc1F/F, CHet, and
CKO mice. Tsc1F/F mice were bred with GFP-LC3 mice to
generate female Tsc1F/F;GFP-LC3/GFP-LC3 mice, which were
used in the breeding with male CHet mice in GFP-LC3 puncta
experiments. Mice were housed at 22 2°C on a 12-hour:12-
hour light/dark cycle under pathogen-free conditions. Local,
state, and federal regulationswere followed formouse handling.
Mice were euthanized by overdose of carbon dioxide. The
investigators who analyzed the various bone parameters were
blind to the identity of the mice. All experimental procedures
were approved by the Institutional Animal Care and Use
Committee at the University of Michigan.
Skeleton preparation
Skeleton preparation was performed as reported.(26)
Micro–computed tomography analysis
Male Tsc1F/F, Osx-Cre, CHet, and CKO mice were euthanized at
the age of 1month (n¼ 9 for each group). Femurswere analyzed
by micro–computed tomography (mCT) as reported.(10,27,28) In
brief, the trabecular region of interest (ROI) from the distal
femora was identified as 10% of the bone length starting at the
interface between the growth plate andmetaphyseal trabecular
bone extending into the metaphysis.
Histomorphometry
Histomorphometry measurements were conducted as de-
scribed.(10,27,29,30) All measurements were performed following
the published guidelines.(31) The trabecular ROI from the distal
femora was identified as a 1-mm 0.8-mm rectangle, in the
center of the bone, which was 0.5mm below the growth plate.
RNA extraction and qRT-PCR
RNA extraction and qRT-PCR analyses were performed as
described.(27) For qRT-PCR analyses, equal amounts of cDNA
template were used for SYBR Green PCR Core reagents system
(Qiagen, Valencia, CA, USA). Primer sequences used for qRT-PCR
are provided in Supporting Table S1.
Bone marrow culture
BMSCs were collected from the femur and tibia of 24-day-old to
28-day-old control, Osx-Cre, CHet, or CKO mice. Briefly, bone
marrow were flushed and cultured in a-MEM with 10% FBS for
3 days and rinsed with medium to remove nonadherent cells.
Adherent cells were cultured for 7 to 8 days as described.(10)
Osteoclast differentiation
Bone marrow was flushed from femur and tibia of 1-month-old
control or CKO mice and bone marrow cells were cultured in a-
MEM with 10% FBS for 1 day and nonadherent cells were
cultured with 20 ng/mL M-CSF (#416-ML-010; R&D Systems,
Minneapolis, MN, USA) for 3 days. The medium was replaced
every 48 hours. Bone marrow–derived macrophages (BMMs)
were harvested to induce osteoclast formation. BMMs were
plated (1 104 cells/well in 48-well plates) and treated with or
without 30 ng/mL of RANKL (#462-TEC-010; R&D Systems,
Minneapolis, MN, USA) in the presence of M-CSF (20 ng/mL)
for 4 to 6 days. The cells were fixed and stained using a tartrate
resistant acid phosphatase (TRAP) staining kit (#387A-1KT;
Sigma-Aldrich, St. Louis, MO, USA). Osteoclast-like cells were
defined as pink-colored TRAP-positive multinucleated (>5
nuclei) cells (MNCs).
Osteoblast and osteoclast co-culture
Bone marrow was flushed from femur and tibia of 1-month-old
control, CHet, or CKOmice and bonemarrow cells were cultured
in a-MEM with 10% FBS for 1 day. For bone marrow-derived
osteoblasts, adherent cells were cultured for 10 days with
medium replacement every 48 hours. Nonadherent cells were
cultured in the presence of 20 ng/mL M-CSF for 3 days to
differentiate to BMMs. Themediumwas replaced every 48 hours.
After 3 days, BMMs were plated (0.5 105 cells/well or 1 105
cells/well in 48-well plates) with bone marrow-derived osteo-
blast cells (1 104 cells/well or 2 104 cells/well in 48-well
plates) in the presence of 20 nM 1a, 25-dyhydroxy vitamin D3
(D1530, Sigma-Aldrich, St. Louis, MO, USA) and 1mM prostaglan-
din E2 (P0409, Sigma-Aldrich, St. Louis, MO, USA) to induce the
expression of osteoclastogenic M-CSF and RANKL, and to permit
the osteoclast differentiation for 7 days. The cells were fixed and
stained using a TRAP staining kit. Osteoclast-like cells were
defined as pink-colored TRAP-positive MNCs (>3 nuclei).
Osteoblast differentiation assay
BMSCs were seeded at 100,000 cells per well in a 12-well plate.
Cells were cultured ina-MEMwith 10% FBS containing 50mg/mL
of ascorbic acid and 10mM of beta-glycerophosphate. The
medium was changed every other day. The alkaline phosphatase
(ALP) staining and Alizarin Red (AR) staining was performed at
day 7 and day 21, respectively, as described.(10)
Proliferation assay
BMSCs were seeded at 80,000 cells per well in a 12-well plate
with osteogenic differentiation medium. Cells were trypsinized
on day 3 or day 7 and cell numbers were counted. For
immunostaining using anti-Ki67 antibody (#9129; Cell Signaling
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Technology, Beverly, MA, USA), cells were fixed with 4%
paraformaldehyde and immunostained on day 3 or day 7 as
described.(10)
Western blot
Western blot was performed as described.(32) Antibody informa-
tion is described as follows. Anti-TSC1: #4906, Cell Signaling
Technology, Beverly, MA, USA; anti-b-catenin: #8480, Cell
Signaling Technology, Beverly, MA, USA; anti-active b-catenin:
#8814, Cell Signaling Technology, Beverly, MA, USA; anti-p-GSK-
3b (S9A): #5558, Cell Signaling Technology, Beverly, MA, USA;
anti-GSK-3b: #9315, Cell Signaling Technology, Beverly, MA,
USA; anti-p-S6: #5364, Cell Signaling Technology, Beverly, MA,
USA; anti-S6: #2217, Cell Signaling Technology, Beverly, MA, USA;
anti-p62: #5114, Cell Signaling Technology, Beverly, MA,
USA; anti-LC3: #2775, Cell Signaling Technology, Beverly, MA,
USA; anti-Vinculin: #V4505, Sigma-Aldrich, St. Louis, MO, USA;
anti-a-Tubulin: #T6199, Sigma-Aldrich, St. Louis, MO, USA; and
anti-Notch1: #ab52627; Abcam, Cambridge, MA, USA.
BMSC adipocyte differentiation
BMSCs were seeded at 400,000 cells/well in a 12-well plate with
adipogenic differentiation medium. Briefly, cells were cultured in
a-MEMwith 10% FBS containing 1mM dexamethasone, 5mg/mL
troglitazone, 50mM 3-isobutyl-1-methylxanthine, and 1mg/mL
insulin for 2 days and then cultured in a-MEM with 10% FBS
containing 1mg/mL insulin for 3 days. Oil-red O staining was
performed as described.(10)
Starvation
Amino acid-free Earle’s balanced salt solution (EBSS,
#SH30029.02; Hyclone Laboratories, Logan, UT, USA) without
FBS was used as starvation medium.
siRNA knockdown
Lipofectamine RNAi MAX (Invitrogen, Carlsbad, CA, USA) was
used to transfect BMSCs or mouse embryonic fibroblasts (MEFs)
with siRNA in Opti-MEM medium (Invitrogen). The efficiency of
transfection was monitored by Western blot. The sequences of
siRNA were as follows: Notch1: sense: 50-AACAGCAUCAUCC
AAAUCCAACUGA-30, and anti-sense: 50-UCAGUUGGAUUUGG
AUGAUGCUGUUUG-30. Nonspecific siRNA sequences were used
as negative controls: sense: 50-CGUUAAUCGCGUAUAAUACGCG
UAT-30, and antisense: 50-AUACGCGUAUUAUACGCGAUUAACG
AC-30. (TriFECTa DsiRNA Duplex; Integrated DNA Technologies
[IDT], Coralville, IA, USA).
Statistical analysis
For two-test group comparison, Student’s t test was used. For
the comparison in multiple groups, one-way ANOVA with
Tukey’s multiple comparison tests were performed using
GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA,
USA). For both tests, p< 0.05 was considered to be significant.
Results
Deletion of Tsc1 in Osterixþ cells leads to decreased
trabecular bone mass in mice
To determine the function of Tsc1 in early osteoblast lineage
cells, we generated Tsc1 CKO mice with Osterix-Cre (Osx-Cre),
which has Cre recombinase activity in osteoprogenitor cells.(22)
Floxed Tsc1 (Tsc1F/F), Osx-Cre/þ (Osx-Cre), Tsc1F/þ;Osx-Cre mice
(CHet), and Tsc1F/F;Osx-Cre (CKO) mice were generated as
described in Materials and Methods. To determine the effects of
Tsc1 deletion on early skeleton development, whole-mount
skeleton staining was performed on newborn mice. Major
skeletal elements appeared normal in CKO mice at birth
(Supporting Fig. S1). CKO mice had similar body weight
compared to other littermate mice at the neonatal stage
(Supporting Fig. S2), but grew slower after birth (Supporting
Fig. S3). At 1 month old, CKOmice were lighter than Tsc1F/F, Osx-
Cre, and CHet mice (Supporting Fig. S3). The CKO mice died
around 1 month of age due to an unidentified reason. Next, mCT
analysis was performed to determine the effects of Tsc1 deletion
on bone structure. CKO mice had a 35% to 60% decrease in
femoral trabecular bone volume fraction (BV/TV) compared to
Tsc1F/F, Osx-Cre, and CHet mice (Fig. 1A, B), indicating Tsc1
deletion led to decreased femoral trabecular bone mass.
Trabecular bone mass decrease in CKO was contributed by
the decrease in both trabecular number (Tb.N) (Fig. 1C) and
trabecular thickness (Tb.Th) (Fig. 1D). Correspondingly, CKO
had a 45% to 139% increase in trabecular spacing (Tb.Sp)
compared to Tsc1F/F, Osx-Cre, and CHet mice (Fig. 1E). There was
a small decrease in trabecular TMD in CKO compared to Tsc1F/F
but not to Osx-Cre and CHet mice (Fig. 1F). In contrast to the
decrease in trabecular bonemass, CKOmice had a small increase
in femoral cortical bone mass as well as calvarial bone mass
compared to Tsc1F/F, Osx-Cre, and CHet mice (data not shown).
The increase in cortical bone mass was consistent with a
previous report using similar mouse model, which ascribed the
cortical bone mass increase to enhanced proliferation in TSC1-
deficient osteoblasts.(19) Altogether, our data showed that Tsc1
deletion in osterix-expressing cells led to a significant decrease
in femoral trabecular bone mass.
Decreased femoral trabecular bone mass in Tsc1-deficient
mice is due to decreased osteoblastogenesis in association
with increased osteoclastogenesis and increased bone
marrow adipogenesis
Consistent withmCTmeasurements, histomorphometry analysis
on femurs showed a 77% decrease in BV/TV (Fig. 2A), a 71%
decrease in Tb.N (Fig. 2B), a 22%decrease in Tb.Th (Fig. 2C), and a
441% increase in Tb.Sp (Fig. 2D) in CKOmice. At the cellular level,
there was a 40% decrease in both osteoblast number (N.Ob)
(Fig. 2E) and surface (Ob.S/BS) (Fig. 2F), and a 46% and 60%
increase in osteoclast number (N.Oc) (Fig. 2G) and surface(Oc.S/
BS) (Fig. 2H), respectively. Notably, there was a 13-fold increase
in bone marrow adipocyte number in CKO mice (Fig. 2I, J). In
addition, there was a slight increase in the length of
hypertrophic zone of femoral growth plate in CKO mice
(Supporting Fig. S4). Collectively, compromised osteoblasto-
genesis in association with increased adipogenesis and
increased osteoclastogenesis contributed to decreased femoral
trabecular bone mass in CKO mice in vivo.
Increased osteoclastogenesis in Tsc1-deficient mice is
associated with increased Mcsf expression
To understand the mechanism of increased osteoclastogenesis
in CKO bone, we first determined the effect of Tsc1 deletion in
Osterix-expressing cells on the osteoclastogenic potential of
bone marrow cells. Data showed that bone marrow cells of CKO
mice had the same osteoclastogenic potential as that of control
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(CTR) mice (Fig. 3A), which supported a cell nonautonomous
effect of Tsc1 deletion in osteoblastic lineage on osteoclastic
lineage. Next, we determined the effect of Tsc1 deletion on the
expression of Opg, Rankl, and Mcsf, three important osteoblast-
secreted mediators of osteoclastogenesis in both BMSCs (Fig. 3B)
and femur (Fig. 3C). Because theexpressionof bothOpgandRankl
was increased similarly, their changes were unlikely responsible
for the increased osteoclastogenesis. However, there was a
significant increase in Mcsf expression in TSC1-deficient BMSCs
and femur. Mcsf is a positive regulator for the proliferation,
differentiation, and survival of monocytic lineage cells.(33) Thus,
increasedMcsf expressionmaybe at least partially responsible for
the enhanced osteoclastogenesis in CKO bone. To further
determine whether osteoblasts/BMSCs in CKO mice were
responsible for the increased osteoclastogenesis, we performed
a co-culture experiment using both BMSCs and BMMs. Our data
showed that compared to the BMSCs isolated from control and
CHet mice, BMSCs isolated from CKO mice could better support
the osteoclastogenesis of BMMs isolated from control mice
(Fig. 3D) or CKO mice (Supporting Fig. S5).
Tsc1 deletion leads to decreased proliferation, compromised
osteogenic differentiation, and enhanced adipogenic
differentiation of BMSCs
To further determine the mechanisms responsible for the
decreased osteoblastogenesis observed in the femoral trabecu-
lar bone of CKO mice, we first investigated the effect of Tsc1
deletion on BMSC proliferation. BMSCs from CKO mice had
efficient Tsc1 deletion and expected increase in the level of
phosphorylated S6, an mTORC1 activation marker (Fig. 4A).
TSC1-deficient BMSCs had decreased proliferation ability shown
by decreased cell number and decreased percentage of Ki67-
positive cells (Fig. 4B–D). Of note, BMSCs isolated from CHet
mice (Fig. 4B) or Osx-Cre mice (Supporting Fig. S6) had
comparable proliferation compared to controls.
Next, we determined the effect of Tsc1 deletion on the
osteogenic differentiation of BMSCs.
Deletion of TSC1 in BMSCs (Fig. 5A) resulted in significantly
compromised early and terminal differentiation (Fig. 5B, C).
TSC1-deficient BMSCs had decreased mRNA expression of
master osteoblastic transcription factors Runx2 and Osx, as
well as most osteoblast differentiation marker genes, including
Alpl, Bsp, and ColIa1 (Fig. 5D). Notably, Ocn expression was
increased in TSC1-deficient BMSCs, which was opposite to other
marker genes. The mechanism of increased Ocn expression
in TSC1-deficient osteoblasts is unknown. Similarly, others
reported an increase of Ocn expression in TSC2-deficient
osteoblasts, which had compromised osteogenic differentiation
in vitro.(18) Altered FoxO1 activity due to dysregulated mTOR
was suggested to be the mechanism responsible for this
osteoblast differentiation-independent increase of Ocn expres-
sion.(18) Thus, our data suggested that compromised osteoblast
differentiation likely contributed to the decreased bone mass in
CKO mice in vivo.
To determine the mechanism of increased bone marrow
adipocytes in Tsc1 CKO mice, we first assessed the effect of Tsc1
deletion on the adipogenic potential of BMSCs. As expected,
TSC1 was effectively deleted in CKO culture and decreased in
CHet culture with corresponding increase in p-S6 level (Fig. 5E).
In response to adipogenic stimuli, the TSC1-deficient BMSCs
exhibited significantly enhanced adipogenic differentiation
compared to CTR and CHet BMSCs (Fig. 5F, G). mRNA levels
of adipogenic differentiation marker genes and master adipo-
cyte transcription factors including peroxisome proliferator-
activated receptor gamma (Pparg), fatty acid binding protein 4
(Fabp4, also known as Ap2), adiponectin (Adipoq), CCAAT/
enhancer-binding protein alpha (Cebpa, also known as C/EBPa),
and zinc finger protein 423 (Zfp423) were increased in TSC1-
deficient BMSCs (Fig. 5H). Notably, even before the adipogenic
induction at the start of the culture (day 0), themRNA expression
levels of these adipogenic genes were significantly increased.
Fig. 1. Tsc1 deletion leads to decreased femoral trabecular bone mass. mCT analysis in femurs of 1-month-old male Tsc1F/F, Osterix-Cre/þ (Osx-Cre),
Tsc1F/þ;Osx-Cre/þ (CHet), and Tsc1F/F;Osx-Cre/þ (CKO) mice. (A) Representative mCT image of femoral trabecular bone. (B) BV/TV. (C) Tb.N. (D) Tb.Th. (E)
Tb.Sp, trabecular spacing. (F) TMD. p< 0.05, p< 0.01, p< 0.001, p< 0.0001, #0.05< p< 0.1, n¼ 9. Values are shown as meanþ SE. BV/
TV¼bone volume per tissue volume; Tb.N¼ trabecular number; Tb.Th¼ trabecular thickness; Tb.Sp¼ trabecular spacing; TMD¼ tissuemineral density.
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This indicated that TSC1-deficient BMSCs had acquired some
extent of intrinsic adipocyte phenotype.
Tsc1 deletion leads to mTORC1-dependent
downregulation of Wnt/b-catenin signaling
Wnt/b-catenin signaling plays important role in both osteo-
blastogenesis and adipogenesis.(5,6) It has been reported that b-
catenin deletion in Osterix-expressing cells results in decreased
femoral trabecular bone mass in association with increased
bonemarrow adiposity.(7,8) Thus, we examined the effect of Tsc1
deletion on b-catenin level. Our data showed significantly
reduced total and active b-catenin protein levels in TSC1-
deficient BMSCs (Fig. 6A). BMSCs isolated from CHet mice
(Fig. 6A) or Osx-Cre mice (Supporting Fig. S7) had comparable b-
catenin protein levels compared to controls. The mRNA
expression level of Wnt/b-catenin target genes including
Axin2, Cnx43, and Lef1 was decreased in TSC1-deficient BMSCs
(Fig. 6B). Thus, Tsc1 deletion in BMSCs downregulates Wnt/b-
catenin signaling by decreasing b-catenin protein level.
Treatment with rapamycin, an mTORC1 inhibitor, increased
the b-catenin protein level in TSC1-deficient BMSCs (Fig. 6C),
suggesting that the downregulation of b-catenin protein in
TSC1-deficient BMSCs was mTORC1-dependent. To elucidate
whether the regulation of Wnt/b-catenin signaling pathway by
TSC1 is specific to BMSCs, we determined the effect of Tsc1
deletion onWnt/b-catenin signaling pathway in MEFs. Similar to
BMSCs, Tsc1–/– MEFs had decreased b-catenin protein level
(Fig. 6D) and decreasedmRNA expression level ofWnt/b-catenin
target genes (Fig. 6E). Rapamycin treatment increased b-catenin
protein level in Tsc1–/– MEFs (Fig. 6F). Altogether, our data
demonstrated that Tsc1 deletion led to mTORC1-dependent
reduction of b-catenin protein level and downregulation of the
Wnt/b-catenin signaling pathway in both BMSCs and MEFs.
b-catenin downregulation in TSC1-deficient cells is
non-canonically regulated but Notch1-dependent
To elucidate the mechanisms underlying the b-catenin down-
regulation in TSC1-deficient cells, we determined the effect of
Tsc1 deletion on the response to exogenous canonical Wnt
ligand in both BMSCs (Fig. 7A) and MEFs (Fig. 7B). As expected,
the control cells had increased b-catenin level upon Wnt3a
treatment. However, TSC1-deficient BMSCs and MEFs had a
blunted increase in b-catenin protein level upon Wnt3a
treatment, indicating that the b-catenin downregulation in
TSC1-deficient cells was likely not due to the deficiency
in Wnt ligands. Downstream of the Wnt ligands and receptors,
Fig. 2. Histomorphometric analysis of control and Tsc1 CKOmice. (A) BV/TV, bone volume per tissue volume. (B) Tb.N. (C) Tb.Th. (D) Tb.Sp. (E) N.Ob/BS. (F)
Ob.S/BS. (G) Oc.S/BS. (H) N.Oc/BS. (I) N.Ad/BA. (J) Histological images showing bone marrow adipocytes (indicated by arrows). p< 0.05, n¼ 9.
Scale bar¼ 50mm. Values are shown as meanþ SE. Tb.N¼ trabecular bone number; TbTh¼ trabecular thickness; Tb.Sp¼ trabecular spacing;
N.Ob/BS¼ osteoblast number per bone surface; Ob.S/BS¼ osteoblast surface per bone surface; Oc.S/BS¼ osteoclast surface per bone surface;
N.Oc/BS¼ osteoclast number per bone surface; N.Ad/BA¼ adipocyte number per bone area; CTR¼ control (Tsc1F/F).
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b-catenin is regulated by a destruction complex in which GSK3 is
an important component.(5) To determine whether the down-
regulation of b-catenin in TSC1-deficient cells was mediated by
increased activity of GSK3 destruction complex, phosphor-
GSK3b (S9) level was analyzed. Phosphorylation of the N
terminal Ser 9 of GSK3b leads to the inhibition of GSK3 function.
Thus the increase in the phosphor-GSK3b (S9) level is expected
to have lowerb-catenin degradation activity, whichwould result
in higher b-catenin level.(34) Intriguingly, phosphor-GSK3b (S9)
was significantly increased in TSC1-deficient BMSCs and MEFs
(Fig. 7C), suggesting that the downregulation of b-catenin in
TSC1-deficient cells was not mediated through canonical GSK
destruction pathway.
mTORC1 signaling can enhance Notch signaling and increase
Notch1 expression.(35) Overexpression of Notch intracellular
domain can impair osteoblast differentiation and inhibit Wnt/
b-catenin signaling.(36) Thus, we determined to what extent that
the Notch1 signaling was altered in TSC1-deficient cells. In
contrary to the decrease in b-catenin, TSC1-deficient BMSCs had
significantly increased Notch1 protein level (Fig. 7D) in
association with an increase in mRNA expression level of Hey1
and Jagged1 (Fig. 7E), two downstream target genes of Notch1
signaling. In MEFs, a similar inverse relationship between the
protein level of b-catenin and Notch1 as well as the increase of
Notch signaling due to Tsc1 deletion was observed (Fig. 7F, G).
Notch1 protein canmediate GSK3-independent activeb-catenin
degradation in stem and colon cancer cells through lysosomal
degradation.(37) Thus, we next determined whether TSC1
regulated b-catenin through Notch1. Using siRNA approach,
we deleted Notch1 in Tsc1–/– MEFs cells and found that Notch1
knockdown increased the active and total b-catenin level
(Fig. 7H). In association with the increase in active b-catenin
Fig. 3. Tsc1 deletion in Osterix-expressing cells does not affect the osteoclastogenic potential of bone marrow cells but increases Mcsf expression. (A)
BMMswere cultured in the presence of 20 ng/mL ofM-CSF and 30 ng/mL of RANKL for indicated days and stained for TRAP. Numbers of TRAPþMNCs (>5
nuclei) were counted (right panel). Scale bar¼ 200mm. (B, C) Quantitative PCR analyses of themRNA levels ofOpg, Rankl,Mcsf in BMSCs (B) and femur (C).
(D) A total of 100,000 BMMs isolated fromCTRmicewere culturedwith 20,000 BMSCs isolated fromCTR, CHet, and CKOmice in the presence of 20 nM 1a,
25-dyhydroxy vitamin D3 and 1mM prostaglandin E2 for 7 days. Numbers of TRAP
þ MNCs (>3 nuclei) were counted (right panel). Scale bar¼ 100mm.
p< 0.05, n¼ 3. Values are shown as meanþ SE. TRAP¼ tartrate resistant acid phosphatase; TRAPþ¼ TRAP-positive; MNC¼multinucleated cell;
BMM¼bone marrow–derived macrophage; CTR¼ control (Tsc1F/F).
2026 CHOI ET AL. Journal of Bone and Mineral Research
level, there was increased mRNA expression level of Wnt/b-
catenin target genes (Fig. 7I). In TSC1-deificent BMSCs, Notch1
knockdown led to an increase in active b-catenin protein level
(Fig. 7J), an increase in the mRNA expression level of Wnt/b-
catenin target genes (Fig. 7K) and an inverse decrease in the
mRNA expression level of adipogenic factors (Fig. 7L). Alto-
gether, our data showed thatb-catenin downregulation in TSC1-
deficient cells was mediated by increased Notch1 protein level.
Tsc1 deletion leads to autophagy inhibition and Notch1
is an autophagy target
Last, we determined the mechanism of Notch1 regulation by
Tsc1 deletion. mTORC1 is a master regulator of autoph-
agy(38–40) and Tsc1 deletion can suppress autophagy as a result
of mTORC1 activation.(41–43) It is reported that plasma
membrane-resident Notch1 can be degraded by autophagy
and autophagy inhibition can increase Notch1 level on the
plasma membrane in human embryonic kidney cells.(44) In
addition, autophagy deficiency can trigger precocious Notch
signaling activation during Drosophila oogenesis.(45) Thus, we
hypothesized that TSC1 regulates Notch1 through the
autophagy pathway in BMSCs. To test this hypothesis, we
first determined the effect of Tsc1 deletion on BMSC
autophagy. In response to starvation stimulation, there was
increased LC3-II level in both control and TSC1-deficient
BMSCs, however, the increase of LC3-II in TSC1-deficient cells
was milder, indicating a defect in autophagy response
(Fig. 8A). Our data also showed a defective autophagy flux
in CKO cells (Fig. 8B). Furthermore, we examined GFP-LC3
puncta formation in response to starvation in isolated BMSCs
from CKO and control mice containing transgenic GFP-LC3. As
expected, robustly increased GFP-LC3 puncta in BMSCs was
observed after starvation treatment, but this increase was
significantly blunted in BMSCs isolated from CKO;GFP-LC3
mice compared to that from CTR;GFP-LC3 mice (Fig. 8C, D).
Thus, the autophagy function was suppressed in TSC1-
deficient BMSCs.
To determine whether the suppressed autophagy in TSC1-
deficient BMSCs is responsible for the upregulation of Notch1
and the inverse downregulation of active b-catenin, the TSC1-
deficient BMSCs were subject to autophagy induction either
by starvation (Fig. 8E) or being treated with rapamycin (Fig. 8F)
or Tat-Beclin1, a novel autophagy-inducing peptide(46)
(Fig. 8G). In response to the autophagy stimuli, there was a
significant decrease in Notch1 protein in association with
autophagy activations as indicated by the increase in LC3-II
level and decrease in p62 level, indicating Notch1 is an
autophagy target in BMSCs. In contrast to the significant
decrease in Notch1 level, there was a moderate increase in the
active b-catenin level in response to the autophagy activation.
Thus, autophagy activation in TSC1-deficient BMSCs led to
increased autophagic degradation of Notch1, which in turn
restored the decreased active b-catenin level by damping the
Fig. 4. TSC1-deficient BMSCs have decreased proliferation. BMSCs were isolated from femur and tibia of CTR, CHet, and CKO mice as described in
Materials andMethods. (A) TSC1was efficiently deleted in BMSCs in associationwith increased phosphor-S6 level in CKOgroup as shown byWestern blot
analysis. (B) Quantitation of cell number cultured for 3 and 7 days in osteogenic medium. n¼ 3 per group. (C) Representative merged fluorescent images
of Ki67 (red) and DAPI (blue) staining in CTR and CKO osteoblasts at 3rd and 7th day, in the same cultures system as B. Scale bar¼ 50mm. (D)
Quantification of Ki67-positive (Ki67þ) in the cultures shown in C. n¼ 3 per group, p< 0.05. Values are presented as meanþ SE. DAPI¼ 4,6-diamidino-2-
phenylindole; CTR¼ control (Tsc1F/F).
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Notch1-mediated GSK3b-independent degradation of active
b-catenin, which is shown to occur in lysosomes.(37) Due to the
nonselective strong autophagy activation by starvation,
rapamycin, or Tat-Beclin1treatment, b-catenin could be
directly subject to autophagic degradation. Thus, the b-
catenin increase mediated by the downregulation of Notch1
was counterbalanced by the autophagic degradation of b-
catenin. Hence, the increase of active b-catenin level in TSC1-
deficient BMSCs in response to these strong autophagy stimuli
appears very mild. To further support the notion that
autophagy could regulate b-catenin level through Notch1,
we determined the effect of autophagy suppression by
Fig. 5. Tsc1 deletion leads to compromised osteogenic and enhanced adipogenic differentiation in BMSCs. (A) TSC1 was effectively deleted in CKO
BMSCs as shown by Western blot. (B, C) Osteogenic differentiation of BMSCs were analyzed by ALP staining at day 7 (B) and AR staining at day 21 (C).
Images shown were the representatives of five independent experiments. (D) qPCR analysis of the mRNA expression of osteoblast differentiation
markers. p< 0.05, n¼ 3. Values are shown asmeanþ SE. (E) TSC1was effectively deleted in CKO BMSCs and partially deleted in CHet BMSCs as shown by
Western blot. (F) Oil red O staining showed enhanced adipogenic differentiation of TSC1-deficient BMSCs, in adipogenic medium for 5 days. (G) The
quantitation of Oil red O staining described in F. (H) qPCR analysis of the mRNA expression of adipogenic differentiation markers and transcription
factors, in the cultures described in F. p< 0.05, n¼ 3. Values are shown as meanþ SE. ALP¼ alkaline phosphatase; AR¼Alizarin Red; Runx2¼ Runt-
related transcription factor 2; Osx¼ osterix; Alpl¼ alkaline phosphatase; Bsp¼bone sialoprotein protein; ColIa1¼ collagen, type I, alpha 1;
Ocn¼ osteocalcin; CTR¼ control (Tsc1F/F).
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deleting Fip200, an essential autophagy gene, in osterixþ cells
on the b-catenin and Notch 1 level. As expected, Fip200
deletion in BMSCs led to decrease LC3-II protein level (Fig. 8H)
and increased p62 (data not shown). Importantly, autophagy
deficiency led to increased Notch1 level but decreased b-
catenin level (Fig. 8H). This further supports the regulatory axis
of autophagy/Notch1/b-catenin in BMSCs.
Discussion
In this work, we identified a novel signaling cascade regulating
the commitment of BMSCs into osteoblasts versus adipocytes.
Ablation of Tsc1 in Osterix-expressing cells leads to a decrease in
trabecular bone mass and an increase in bone marrow
adipogenesis in association with decreased b-catenin level,
which is mediated by increased Notch1 protein level via
autophagy suppression. It is known that Wnt/b-catenin signal-
ing favors osteoblast over adipocyte lineage commitment.(6–8,22)
Thus, we propose a model (Fig. 9A, B) in which the decreased
Wnt/b-catenin signaling due to the increased Notch1 protein
level via autophagy suppression in TSC1-deficient BMSCs
accounts for the dysregulated osteoblast-adipocyte lineage
commitment and subsequent osteoporotic phenotype in
association with increased marrow adipose tissue. It is known
that Osterix-Cre transgene causes some skeletal development
defects.(26,47,48) Our data showed that Osterix-Cre does not affect
in vitro BMSC proliferation (Supporting Fig. S6) and osteogenic
differentiation(26); neither did it affect the Notch1 and b-catenin
level in BMSCs (Supporting Fig. S7). Thus, we concluded that
the Tsc1 deletion itself was the major contributor of both the
in vivo bone phenotype of Tsc1-deficient mice and the in vitro
differentiation defect of Tsc1-deficient BMSCs. However, be-
cause the CHet mice had similar decrease in trabecular bone
mass and body weight to Osterix-Cre mice, the trabecular bone
mass decrease in CKO mice was likely due to the combined
effects of Tsc1 deletion and the presence of Osterix-Cre
transgene.
mTORC1 andWnt/b-cateninmediate two important signaling
pathways that have significant impacts on major cellular
functions. The connection between mTORC1 signaling and
Wnt signaling is not completely new. It has been shown thatWnt
signaling increases mTORC1 activity through the inhibition of
GSK3 kinase that promotes TSC1/TSC2 activity by directly
phosphorylating TSC2.(49) Our data revealed a novel interaction
between these two types of signaling in which mTORC1
activation downregulates Wnt/b-catenin signaling, thus form-
ing a negative feedback loop. Furthermore, our data showed
that this downregulation of Wnt/b-catenin signaling by
mTORC1 activation is mediated through a GSK3-independent
but Notch1-dependent mechanism via autophagy suppression.
The mammalian skeleton contains cortical and trabecular
bone. Even though they are generated by the same cell types,
Fig. 6. Tsc1 deletion leads to mTORC1-dependent downregulation of Wnt/b-catenin signaling. (A) BMSCs were analyzed by Western blotting with
indicated antibodies. (B) qPCR analysis of the mRNA expression of b-catenin target genes Axin2, Cnx43, and Lef1 in BMSCs. n¼ 3. (C) TSC1 CKO BMSCs
were treated with rapamycin at indicated concentration for 24 hours and analyzed by Western blotting with indicated antibodies. (D) MEF TSC1þ/þ and
TSC1–/– cells were analyzed by Western blotting with indicated antibodies. (E) qPCR analysis of the mRNA expression of b-catenin target genes Axin2,
Cnx43, and Lef1 in MEFs. n¼ 3. (F) MEFs were treated with rapamycin at 10 nM or 20 nM for 24 hours and analyzed by Western blotting with indicated
antibodies. For B and E, p< 0.05, values are shown as meanþ SE. CTR¼ control (Tsc1F/F).
Journal of Bone and Mineral Research TSC1 GOVERNS BMSC DIFFERENTIATION 2029
there are significant differences between them in both
structure(50,51) and response to external factors such as athletic
training(52) and parathyroid hormone deficiency and excess.(53)
In addition, cortical and trabecular bone have different
microenvironments and modeling/remodeling mechanisms.
Cortical bone growth mainly occurs through periosteal
expansion at periosteum. On the other hand, trabecular bone
growth mainly occurs in the bone marrow, which contains
multipotent BMSCs that can differentiate into osteoblasts and
adipocytes. Despite these significant differences, very little is
known about the cellular and molecular mechanisms that are
responsible for the differential regulation of cortical versus
Fig. 7. b-catenin downregulation in TSC1-deficient cells is non-canonically regulated and Notch1-dependent. (A) BMSCs were treated with Wnt3a at
indicated concentration for 24 hours and (B) MEFs were treated with Wnt3a at indicated concentration for 48 hours and analyzed by Western blotting
with indicated antibodies. (C) The cell lysates from BMSCs (CTR and CKO) and MEFs (Tsc1þ/þ and Tsc1–/–) were subjected to immunoblot analysis with
indicated antibodies. (D) BMSCs or (F) MEFs were analyzed byWestern blotting with indicated antibodies. (E, G) qPCR analysis of themRNA expression of
Notch1 target genes Hey1 and Jagged1 in BMSCs (E) or MEFs (G). n¼ 3, p< 0.05. (H, I) Control siRNA (siCon or siControl) and siNotch1 (1 and 2) (10 or
20 pmol) were transduced to Tsc1–/– MEFs for 24 hours and analyzed by Western blotting with indicated antibodies (H) and qPCR analysis of the mRNA
expression of b-catenin target genes using 10 pmol siControl and siNotch1-1 (I). (J–L) siControl and siNotch1-1 at 10 pmol were transduced to TSC1-
deficient BMSCs for 24 hours and analyzed by Western blotting with indicated antibodies (J) and qPCR analysis of the mRNA expression of b-catenin
target genes (K) and adipocyte marker genes (L). For E, G, I, K, and L, n¼ 3, p< 0.05. Values are shown as meanþ SE. CTR¼ control (Tsc1F/F).
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trabecular bone. In this study, we found that Tsc1 deletion in
Osterix-expressing cells decreased trabecular bone mass
but increased cortical bone mass. Mechanistically, our data
showed that TSC1-deficient BMSCs had decreased proliferation,
decreased osteogenic differentiation, and increased adipo-
genic differentiation. In addition, CKO bone had increased
osteoclasts, which further contributed to the decrease in
trabecular bone mass. The molecular mechanisms that
differentially regulate cortical and trabecular bone remain to
be determined.
A recent study also investigated the effect of Tsc1 deletion in
Osterix-expressing cells on bone homeostasis.(19) It is interesting
to note that this study showed that both cortical and trabecular
bone mass is increased in mice at 10 weeks of age when Tsc1 is
deleted in Osterix-expressing cells.(19) The detailed bone analysis
at earlier age such as 1 month old was not reported in that
Fig. 8. TSC1 deletion leads to decreased autophagy in BMSCs. (A) BMSCs were cultured in completemedium or starved for up to 60min and analyzed by
Western blotting with indicated antibodies. (B) Control and TSC1-deficient BMSCs were cultured in the complete medium or starved for 2 hours with or
without 100mM chloroquine. Immunoblot analysis was performed with indicated antibodies. (C) BMSCs isolated from GFP-LC3 transgenic CTR or CKO
micewere cultured in completemedium or starved for 2 hours. The cells were subject to fluorescentmicroscope analysis after fixation and DAPI staining.
Scale bar¼ 50mm. (D) Numbers of GFPþ puncta per cells were counted, p< 0.05. (E) TSC1-deficient BMSCs were starved for 1 hour and analyzed by
Western blotting with indicated antibodies. (F) TSC1-deficient BMSCs were treated with rapamycin (200 nM) for 1 hour and analyzed byWestern blotting
with indicated antibodies. (G) TSC1-deficient BMSCs were treated with control peptide or Tat-Beclin1 peptide (10mM) for 1 hour and analyzed
by Western blotting with indicated antibodies. (H) BMSCs isolated from control (Fip200F/F) and Fip200 CKO (Fip200F/F;Osx-Cre/þ) mice were analyzed by
Western blotting with indicated antibodies. DAPI¼ 4,6-diamidino-2-phenylindole; CTR¼ control (Tsc1F/F).
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research. Our study showed the differential effect of Tsc1
deletion on cortical and trabecular bone at 1 month of age. One
limitation of our work is the early death of the Tsc1 CKO mice
after 1 month of age. This prevented us from determining
whether Tsc1 differentially regulates cortical versus trabecular
bone in a later development stage. The timing of the sudden
death of these otherwise normal Tsc1 CKO mice may suggest
a likely hematopoietic failure. The reason of the early death of
Tsc1 CKO mice remains to be determined. The mechanisms
underlying the likely difference between our study and the
aforementioned study(19) is currently unknown but it may
be related to the difference in genetic background of the mice
(C57BL/6Ncrl versus 129S4/SvJae) as well as the difference in
development stages (1 month versus 10 weeks). If the difference
in trabecular bone phenotype was indeed due to the difference
in genetic background, it highlights the importance of back-
crossing to known genetic background in bone research. On the
other hand, whenever possible, thorough analysis at both earlier
and later developmental stages is desirable to ensure the
complete understanding of bone phenotype. Of note, another
group similarly reported that Tsc1 deletion in Osterix-expression
cells leads to decreased trabecular bone mass in association
with increased bone marrow adipogenesis and decreased
b-catenin protein level in osteoblasts.(54)
It has been reported that the Osx-Cre transgene is also
expressed in the hypertrophic or late proliferating chondro-
cytes.(55,56) Hypertrophic chondrocytes can transdifferentiate
to become osteoblasts contributing to endochondral bone
formation.(57) This raised the possibility that decreased femoral
trabecular bone mass may also be partially contributed by
Tsc1 deletion in chondrocytes. Indeed, our data showed that
CKO mice had slightly elongated hypertrophic zone without
significant change in proliferative zone (Supporting Fig. S4). The
extent of contribution by Tsc1 deletion in chondrocytes to
decreased femoral trabecular bone in our mousemodel remains
to be determined.
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Fig. 9. Proposed model of TSC1 regulation on the balance between osteoblast and adipocyte differentiation in BMSCs. (A) When TSC1 is present, TSC1-
TSC2 complex inhibits mTORC1 activity; PAS develops into autophagosome, which degrades Notch1. In the presence of sufficient b-catenin/Wnt
signaling, BMSCs preferentially differentiate into osteoblasts. (B) When TSC1 is deleted, mTORC1 activity is upregulated, which in turn inhibits the
autophagosome formation and autophagy-mediated Notch1 degradation. Increased Notch1 canmediate the b-catenin degradation through lysosomal
degradation.(37) In the absence of sufficient b-catenin/Wnt signaling, BMSCs preferentially differentiate into adipocytes. PAS¼pre-autophagosomal
structure.
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